Overview of the findings from the European SOHO study

Expert Review of Neurotherapeutics

Volumn 8, Issue 6, 2008, Pages 873-880

  Suarez, David ^a   Haro, Josep Maria ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antipsychotic; Observational study; Schizophrenia; Treatment outcome

Indexed keywords

AMISULPRIDE; CLOZAPINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

AGRANULOCYTOSIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; PATIENT CARE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 45749087224     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.6.873     Document Type: Review

References (49)

1. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr. Bull. 19(2), 287-302 (1993).
2. Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs, I: neuropsychiatric effects. In: Antipsychotic Drugs and Their Side-Effects. Barnes TRE (Ed.). Academic Press, London, UK, 213-247 (1993).
3. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321, 1371-1376 (2000).
4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60, 553-564 (2003).
5. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 43, 135-145 (2000).
6. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361(9369), 1581-1589 (2003).
7. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64(7), 701-723 (2004).
8. Lehman AF, Lieberman JA, Dixon LB et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161(2 Suppl.), 1-56 (2004).
9. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Mosby, St Louis, MO, USA (1996).
10. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol. 20(6), 699-702 (2000).
11. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. 127(8 Pt 2), 757-763 (1997).
12. Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J. Clin. Psychiatry 60, 658-663 (1999).
13. Coley KC, Carter CS, Dapos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J. Clin. Psychiatry 60, 850-856 (1999).
14. Dossenbach M, Erol A, el Mahfoud Kessaci M et al.; IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine,quetiapine, risperidone, and haloperidol. J. Clin. Psychiatry 65(3), 312-321 (2004).
15. Guy W. Clinical global impression. In: ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, MD, USA, 218-222 (1976).
16. Haro JM, Kamath SA, Ochoa S et al.; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. Suppl. 107(416), 16-23 (2003).
17. Williams A. EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 16, 199-208 (1990).
18. Haro JM, Edgell ET, Jones PB et al.; SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr. Scand. 107(3), 222-232 (2003). •• Detailed explanation of the Schizophrenia Outpatient Health Outcomes (SOHO) study design.
19. Haro JM, Edgell ET, Novick D et al.; SOHO advisory board. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand. 111(3), 220-231 (2005). •• Analysis of the 6-month antipsychotic treatment response in the SOHO study.
20. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D; SOHO Study Group. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur. Neuropsychopharmacol. 17(4), 235-244 (2007). •• Analysis of the 3-year antipsychotic treatment discontinuation in the SOHO study and comparison to the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
21. Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J. Clin. Psychopharmacol. 26(6), 571-578 (2006). •• Analysis of the 3-year remission and relapse outcomes in the SOHO study.
22. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr. Bull. 29(1), 33-43 (2003).
23. Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005). •• Core results of the CATIE study. A randomized clinical trial designed to assess antipsychotic treatment effectiveness by treatment maintenance.
24. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's Public Mental Health System: rates of changing medications and prescribing styles. Schizophr. Bull. 28, 17-29 (2002).
25. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med. Care 37, AS81-AS86 (1999).
26. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl.) 155, 230-233 (2001).
27. McEvoy JP, Lieberman JA, Stroup TS et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163(4), 600-610 (2006).
28. Kahn RS, Fleischhacker WW, Boter H et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618), 1085-1097 (2008).
29. Tiihonen J, Walhbeck K, Lönnqvist J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333(7561), 224 (2006). •• Observational study designed to assess antipsychotic treatment effectiveness in schizophrenia by using computerized clinical databases.
30. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441-449 (2005).
31. Haro JM, Ochoa S, Gervin M, Mavreas V, Jones P. Assessment of remission in schizophrenia with the CGI and CGI-SCH scales. Acta Psychiatr. Scand. 115(2), 163-164 (2007).
32. Suarez D, Haro JM, Novick D, Ochoa S. Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. J. Clin. Epidemiol. 61(6), 525-530 (2008). •• Re-analysis of the 3-year remission results of SOHO study by using a novel methodological approach.
33. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63(10), 1079-1087 (2006). •• Core results of the CUTLASS study. A randomized clinical trial designed to assess the effect of antipsychotic treatment on quality of life in schizophrenic patients.
34. Robinson DG, Woerner MG, McMeniman M et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161, 473-479 (2004).
35. Lambert M, Haro JM, Novick D et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr. Scand. 111(3), 232-243 (2005).
36. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinol. 28, 83-96 (2003).
37. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35, 51-68 (1999).
38. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16, 23-45 (2002).
39. Novick D, Bousono M, Suarez D et al.; SOHO Advisory Board. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(6), 972-982 (2005).
40. Parepally H, Chakravorty S, Levine J et al. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital. Prog. Neuropsychopharmacol. Biol. Psychiatry 26(3), 437-440 (2002).
41. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr. Serv. 54(5), 719-723 (2003).
42. Gasquet I, Haro JM, Novick D et al.; SOHO Study Group. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int. Clin. Psychopharmacol. 20(4), 199-205 (2005).
43. Novick D, Haro JM, Suarez D, Lambert M, Lépine JP, Naber D. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl.) 191(4), 1015-1022 (2007).
44. Usall J, Suarez D, Haro JM; the SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 153(3), 225-231 (2007).
45. Curran MP, Perry CM. Spotlight on amisulpride in schizophrenia. CNS Drugs 16(3), 207-211 (2002).
46. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin. Ther. 24, 209-222 (2002).
47. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 22(1), 49-68; discussion 69-72 (2008).
48. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 342(25), 1878-1886 (2000).
49. Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D, Windmeijer F. Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl. Health Econ. Health Policy 5(1), 11-25 (2006).